Chemotherapy does not significantly improve prognosis in pancreatic cancer. New therapeutical approaches involving p53 gene replacement appear to be very encouraging due to the key role of p53 in the cell response to DNA damage. Here, we have evaluated the effectiveness of combining wild-type p53 (wt-p53) gene reintroduction (Ad5CMV-p53) and exposure to two genotoxic drugs, gemcitabine and cisplatin, in several human pancreatic cell lines. The efficiency of the combinations was clearly dependent upon timing, as assessed by cell survival determinations. Although wt-p53 transduction before drug treatment induced chemoresistance, p53 transduction in cells treated previously with gemcitabine increased cytotoxicity. Cell cycle profiles showed significant decreases in the percentage of cells in the S phase as a consequence of arrests provoked by the expression of exogenous p53, reducing the number of cells susceptible to the drug. The sensitivity of cells to cisplatin, which has a lower degree of S-phase specificity, was not modified as much by p53 gene replacement. In contrast, the recognition of the previous drug-induced DNA damage by the newly expressed wt-p53 elicited increases in sub-G 1 populations, consistent with the annexin determinations and bax/bcl-2 ratios observed. Experiments on subcutaneous pancreatic xenografts corroborated the effectiveness of this approach in vivo. Thus, the combination of p53 transduction and chemotherapy, under a correct schedule of administration, appears to be a very promising therapy for human pancreatic cancer. Cancer Gene Therapy (2000) 7, 545-556
P
ancreatic cancer is one of the most aggressive human tumors and is the fourth leading cause of cancer deaths in Europe and North America. 1 There is no curative therapy for patients who are not eligible for surgery. Despite improvements in diagnosis, most patients are not candidates for surgery, and Ͻ5% of all patients survive 5 years. 2 Treatment of this cancer is a great challenge, and new technologies such as gene transfer strategies may lead to new, advantageous approaches. 3, 4 Alterations in the expression of genes affecting cell cycle progression or cell death induction occur in all human cancers. There is increasing evidence that such alterations may modulate the response of the cell to chemotherapy. 5, 6 Most anti-cancer agents induce apoptosis, which implies that tumor cell chemosensitivity may be influenced by the efficiency of the activation of the apoptotic program. 7 The tumor suppressor protein p53, which is most strongly implicated in human cancer, 8, 9 is a key factor in the cell response to DNA damage. 10, 11 The role of p53 in the G 1 checkpoint, where it induces growth arrest mediated by the cyclin-dependent kinase inhibitor p21
Cip1
, is well established. 12, 13 In contrast, controversial results have been published regarding the function of p53 in the G 2 /M checkpoint. 14 -17 Expression of p53 has been associated with growth arrest in the G 2 /M phase of the cell cycle, 14, 15 whereas other authors have reported a positive role of p53 in G 2 exit after ␥-irradiation or treatment with the DNA topoisomerase II inhibitor etoposide. 16, 17 Exactly how p53 induces apoptosis is not as clear. Recently, Polyak et al 18 have suggested a model for p53 apoptosis on the basis of the marked increase in several transcripts in p53-expressing cells.
A number of studies have described the relationship between the status of the endogenous p53 gene in cells and their sensitivity to chemotherapeutic agents (reviewed in Ref. 6 ). However, the link between p53 and sensitivity or resistance to DNA-damaging agents is still debatable. Loss of p53 is linked to resistance in some tumor cells 7, 17, 19, 20 and to increased sensitivity in others. 21, 22 Reintroduction of wild-type p53 (wt-p53) into tumor cells has led to a variety of effects, including growth arrest and apoptosis. [23] [24] [25] Although some tumor cell types, such as uterine carcinoma or head and neck carcinoma cells, unequivocally show p53-induced apoptosis induction, the results obtained for most of tumor cell types are controversial. 6,26 -29 These contradictory results illustrate that the outcome of wt-p53 gene replacement is not a predictable event but rather depends upon the cell system in which p53 is re-expressed.
The introduction of wt-p53 is a promising way to enhance the apoptosis induced by conventional thera-pies, such as chemotherapy and radiotherapy. Indeed, encouraging results have been reported in glioblastoma, liver cancer, and colon cancer. 6, 30 However, there are important exceptions, 31, 32 and the interaction of p53 with the mechanisms of response to conventional therapies is still unclear.
Only a few studies on wt-p53 gene replacement in pancreatic cancer have been reported. The first results were disappointing. Kimura et al 33 did not detect apoptosis in the AsPC-1 pancreatic tumor cell line after retrovirus-mediated wt-p53 transduction both in vitro and in vivo. Moreover, wt-p53 expression did not change the sensitivity of this cell line to four anti-cancer drugs. 33 In contrast, other authors reported cell growth arrest and apoptosis in a high percentage of cells, as a consequence of adenovirus-mediated wt-p53 transduction in different pancreatic tumor cell lines. 34, 35 In the present study, we have assayed combination treatments based on the introduction of the tumor suppressor gene p53 and the exposure to two genotoxic drugs, gemcitabine (GE) and cisplatin (CDDP). Taken together, our results indicate that the efficiency of the combinations of p53 transduction and chemotherapy clearly depends upon the timing of the administration. In all mutant p53 cells, the restoration of p53 functionality in drug-treated cells significantly reinforces the cytotoxicity of genotoxic agents, both in vitro and in vivo, providing a promising way to improve the prognosis of these tumors.
MATERIALS AND METHODS

Construction and preparation of recombinant adenoviruses
The p53 cDNA was fused to a simian virus 40 polyadenylation signal and cloned downstream of the cytomegalovirus promoter in a pACCMVpLpA plasmid. Recombinant adenoviruses (Ad5CMV-p53) were generated by cotransfection of this plasmid with pJM17 into subconfluent cultures of 293 cells using a modified calcium phosphate precipitation technique. Individual viral plaques were isolated and amplified in 293 cells, and recombinant adenovirus plaques containing human p53 cDNA were identified by polymerase chain reaction amplification and restriction enzyme digestion. Virus without insert (Ad-control) was generated in the same way. Ad5RSV-p16 was a kind gift of Dr. J. Fueyo (MD Anderson Cancer Center, Houston, Tex). Viral clones were propagated in 293 cells and recovered after 48 hours by three cycles of freezing and thawing. Titers were determined by plaque assay on 293 cells.
Cell lines, culture, and infection conditions
The NP-9, NP-18, NP-29, and NP-31 cell lines were derived from human pancreatic adenocarcinomas, which had been perpetuated as xenografts in nude mice. 36 Three cell lines harbored a mutant p53 gene (NP-9, NP-18, and NP-31) and the fourth expressed wt-p53 (NP-29). NP-9 and NP-29 were maintained in Dulbecco's modified Eagle's medium:F12 medium (1:1), and NP-18 and NP-31 were maintained in RPMI 1640; all were supplemented with 10% fetal bovine serum and maintained in a humidified atmosphere containing 5% CO 2 at 37°C. Optimal concentrations of virus causing expression in Ͼ90% of cells, without visible toxic effect, were determined previously by infection with Ad5CMV-lacZ and subsequent staining with 5-bromo-4-chloro-3-indolyl ␤-D-galactopyranoside (X-Gal). 35 ␤-galactosidase (␤-gal) measurements ␤-gal protein expression was evaluated colorimetrically by in situ reaction with the ␤-gal substrate X-Gal. Briefly, tumors injected with Ad5CMV-lacZ were fixed with a solution of 4% paraformaldehyde/0.3% Nonidet P-40 in phosphate-buffered saline (PBS) for 8 hours at 4°C, rinsed four times in PBS, and subsequently exposed to the X-Gal solution overnight at 37°C.
Chemosensitivity test
Drug treatments consisted of the incubation of cells with several concentrations of GE or CDDP for 24 hours. GE was a gift from Lilly S.A. (Madrid, Spain) and CDDP was supplied by Sigma (St. Louis, Mo). Cells were seeded in 24-well plates (20,000 cells/well) and allowed to grow for 24 hours before any manipulation. Viral infections were performed by 12 hourincubations in serum-free media, before or after the drug treatment. In all cases, cell number was determined at 72 hours after the drug treatment by counting quadruplicate dishes in an autoanalyzer Multisizer (Coulter, Hialeah, Fla). Drug doseresponse curves for each condition were plotted as relative cell survival, taking the cell count in the absence of the drug as 100%. Drug doses that produced 50% growth inhibition (IC 50 ) and maximal inhibition (I max ) were estimated from doseresponse curves by standard nonlinear regression using an adapted Hill equation. Parameters are expressed as the value Ϯ SE. The overall efficiency of the drug is expressed using the I max /IC 50 ratio, which combines the ability to kill cells (as indicated by the I max parameter) and the efficiency at low doses (from the IC 50 value) in a single parameter.
Western blot analysis
Total cell lysates were obtained by incubation in lysis buffer (250 mM NaCl, 5 mM ethylenediaminetetraacetic acid, 50 mM NaF, 0.1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and 10 g/mL leupeptin in 50 mM tris(hydroxymethyl)aminomethane (pH 7.4)) for 1 hour at 4°C. After centrifugation at 14,000 ϫ g, supernatant proteins (25 g/lane as determined by bicinchoninic acid protein assay) (Pierce, Rockford, Ill) were electrophoretically separated on 15% polyacrylamide-sodium dodecyl sulfide gel and transferred to nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany). Membranes were developed according to the Amersham enhanced chemiluminescence protocol (Amersham, Arlington Heights, Ill). Monoclonal antibody (Ab) against human p53 (Ab-2; Oncogene Science, Cambridge, Mass) and bcl-2 (Santa Cruz Biotechnology, Santa Cruz, Calif) and polyclonal Abs against bax (Santa Cruz Biotechnology) and actin (Sigma) were used as primary Abs; horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulin G (IgG) (Dako, Carpinteria, Calif), HRP-conjugated anti-goat IgG (Santa Cruz Biotechnology), and HRP-conjugated anti-rabbit IgG (Boehringer Mannheim, Indianapolis, Ind) were used as secondary Abs. Relative quantities of bax and bcl-2 were determined using a scanner (Snap Scan 600; Agfa, Mortsel, Belgium) and Phoretix 1D advanced software (Nonlinear Dynamics, Newcastle, UK) for data densitometric analysis.
Cell cycle analysis
All measurements of cell cycle distribution were performed on an Epics-XL flow cytometer (Coulter) equipped with an air-cooled argon ion laser to give 488 nm light. Triplicates of cell cultures were incubated with GE (0.02 M) or CDDP (1.67 M) before or after infection with recombinant adenoviruses. Cells were harvested 72 hours after drug incubation and stained in tris(hydroxymethyl)aminomethane-buffered saline containing propidium iodide (PI) (50 g/mL), ribonuclease A (10 g/mL), and Igepal CA-630 (0.1%) for 1 hour at 4°C. Data from at least 10,000 cells were collected and analyzed by Multicycle software (Phoenix Flow Systems, San Diego, Calif).
Apoptosis assays
Apoptosis was assessed by annexin V-fluorescein isothiocyanate staining (Genzyme, Cambridge, Mass). Pancreatic cell monolayers were treated with GE (0.02 M) or CDDP (1.67 M) for 24 hours and then incubated with 25 multiplicities of infection (MOI) of Ad5CMV-p53. Serum-free medium was used for mock infection. At 36 hours postinfection, 1 ϫ 10 6 cells were collected, washed in PBS, and resuspended in 1 mL of binding buffer containing 50 g/mL annexin V-fluorescein isothiocyanate and 50 g/mL PI (Genzyme). Annexin staining measures the percentage of total apoptotic cells. Annexin staining combined with PI exclusion allows determination of the percentage of early apoptotic cells. Triplicate dishes of each sample were analyzed with an Epics-XL flow cytometer (Coulter). Elite software was used for data analysis.
In vivo experiments
A total of 2 ؋ 10 7 NP-18 cells were injected subcutaneously (s.c.) into the flank region of BALB/c nude mice. After 30 days, the animals were divided into three groups; one group was used as control and only received intraperitoneal and intratumoral (i.t.) injections of saline solution; another group of animals was treated intraperitoneally with 50 mg/kg of GE on days 1, 4, 7, and 10 and was injected i.t. with PBS after 24 hours; the third group received the same doses of drug, plus i.t. injections (4 ϫ 10 L) of Ad5CMV-p53 (2 ϫ 10 9 plaqueforming units/mL) in different areas of the tumor mass at 24 hours after drug administration. Animals were killed 13 days after the end of treatment. Tumors were measured every other day, and volumes were calculated according to the following formula: V(mm 3 ) ϭ A (mm) ϫ B 2 (mm 2 )/2, where B is the smaller dimension. Statistical analysis was performed using Student's t distribution, with significance reported when P was Ͻ.1. Procedures were performed in accordance with recommendations for the proper care and use of the laboratory animals.
RESULTS
Response of pancreatic tumor cell lines to anti-cancer drugs
The effects of GE and CDDP on the cell growth of four cell lines derived from human pancreatic adenocarcinoma were examined. Mutant p53 (NP-9, NP18, and NP-31) and wt-p53 (NP-29) cells were exposed for 24 hours to different concentrations of the drugs. The concentration range for each agent was chosen according to the literature. 37, 38 GE presented IC 50 values in the nanomolar range, whereas CDDP exhibited values in the micromolar range. No clear correlation between endogenous p53 status and chemosensitivity was observed (Table 1) .
Sensitivity to drugs in combination approaches
To examine the influence of the expression of wt-p53 on the cell response to anti-cancer drugs, the mutant p53 NP-9 cell line was transduced with 25 MOI of Ad5CMV-p53 before or after 24 hours of exposure to different concentrations of GE. Dose-response curves were determined by cell counting 72 hours after drug exposure. The Ad5CMV-p53 dose was chosen to maintain cell viability above 50% in cultures that were not treated with drugs. Curves have been normalized to 100% using the untreated mock-infected cells, Ad-control cells, and Ad5CMV-p53-infected cells as references, respectively, to show only the change in the drug effect due to the presence of p53, without considering the inhibition due to p53 alone. Dose-response curves showed that GE was less effective in p53-transduced cells than in control ones. In contrast, cell transduction after drug exposure rendered the cells more sensitive to the drug (Fig 1A) . This observation is consistent with the IC 50 and I max /IC 50 values (Table 1) . Similar results were obtained in identical experiments performed with the mutant p53 NP-31 cells (Fig 1A) .
Changes in the cell cycle profile helped to explain this differential behavior. Cytometric profiles showed that untransduced NP-9 cells incubated with GE were accu- †An anormal single strand conformation polymorphism pattern was evidenced in multiple experiments; no mutation was detected by direct sequencing and/or sequencing of the polymerase chain reaction product. Figure 1 . Dose-response curves and cell cycle profiles of NP-9 cells transduced with Ad5CMV-p53 before and after GE treatment. A: Dose-response curves for GE. NP-9 cells were seeded in quadruplicate (20,000 cells/well) in 24-well culture plates; after 24 hours, the cells were infected with 25 MOI of Ad5CMV-p53 or Ad-control for 12 hours. a: After viral infection, cells were incubated in the presence of the indicated concentrations of GE for 24 hours. b: Alternatively, cells were firstly exposed to the drug for 24 hours; after drug removal, cells were mulated during the S phase, as expected. In contrast, profiles obtained when cells were transduced with Ad5CMV-p53 showed a significant G 1 arrest that was maintained after drug treatment. This indicates that the decrease in the S-phase population induced by exogenous p53 significantly prevents the drug action. In contrast, the adenovirus-mediated reintroduction of wt-p53 after drug treatments did not lead to the G 1 arrest observed in the untreated Ad5CMV-p53-transduced cells, but provoked a significant shift to the sub-G 1 region, indicative of apoptosis commitment (Fig 1B) .
The G 1 arrest induced by the tumor suppressor p16 (a specific inhibitor of cyclin-dependent kinase 4/6-cyclin D complexes) was used to verify the involvement of this arrest in the chemoresistance induced by p53 when transduction was performed before GE exposure. Experiments using a wt-p16-containing adenovirus (Ad5RSV-p16) instead of the Ad5CMV-p53 were performed. The G 1 arrest (81.0% cells in G 1 ) produced by p16 overexpression was maintained when cells were subsequently incubated with GE (data not shown). A marked decrease in the sensitivity to the drug was observed (Fig 2A) , similar to the behavior observed in p53-transduced cells. In contrast, the transduction of NP-9 cells with Ad5RSV-p16 after GE incubation did not modify the dose-response curve obtained in control cells, and did not modify its parameters (Fig 2B) .
p53 combinations that were identical with those described above for GE were carried out with other genotoxic drug, CDDP, which has a lower degree of S-phase specificity. The results pointed out that the resistance to CDDP induced by p53 transduction before drug exposure was very weak. Cells transduced after drug exposure showed increases in chemosensitivity, although the increases were lower than those observed for GE. (Fig 3A) . As for GE, results with NP-31 cells were very similar to those obtained with NP-9 cells ( Fig  3A) . The analysis of cell cycle profiles was consistent with the cell survival observed. The exposure to CDDP accumulated the cells in G 2 /M phase, as expected. Moreover, CDDP treatments of p53-transduced cells induced changes in the cell cycle profiles, which reflected the ability of this drug to act on arrested cells, in contrast to GE. The transduction performed after the drug incubations allowed the cells to exit from G 2 /M to G 1 and sub-G 1 regions, although the changes were smaller than with GE (Fig 3B) .
Influence of endogenous status of p53
To establish the influence of the endogenous status of p53, we measured the effect of overexpressing p53 in three cell lines pretreated with GE or CDDP: NP-18 and NP-31 (both p53 mutants) and NP-29 (wt-p53). The Table 2 . Significant changes were again observed for the parameters corresponding to mutant p53 cells, whereas no significant variations were detected in NP-29 cells.
In pretreated NP-18 cells, the subsequent p53 transduction caused a massive shift from S phase, where cells had accumulated, to the sub-G 1 region; this shift was even higher than that observed in NP-9 cells (Fig 4A) . In contrast, in NP-29 cells the infection with Ad5CMV-p53 after GE incubation had no effect on the cell cycle profile obtained in the treatment with the drug alone, indicating that in this cell line, neither endogenous nor exogenous wt-p53 was able to activate apoptosis pathways (Fig 4B) .
Determination of apoptosis
Apoptosis levels were measured by annexin labeling 36 hours after mock infection or Ad5CMV-p53 infection. The optimal time of the analysis was determined previously by time-course experiments performed from 6 to 96 hours after the treatment (data not shown). The reintroduction of wt-p53 in pretreated mutant p53 cells led to significant increases in the apoptotic levels with respect to the apoptosis observed in cultures treated with drugs alone. These differences indicate that p53 can induce apoptosis that chemotherapy alone cannot (Table 3). No significant variations by p53 reintroduction were observed in NP-29 cells.
To determine the involvement of bax and bcl-2 genes in the apoptosis induced in our model, protein levels were determined by Western blotting and ratios were calculated by densitometry (Fig 5) . Significant increases in the bax/bcl-2 ratio were observed after infection with p53-expressing adenovirus in drug-treated cultures. No significant variations in the ratios were detected between control cells and cells treated with the drugs alone, which is consistent with the results obtained in the annexin test.
In vivo experiments
The efficiency of adenoviral transduction in vivo was determined using an adenovirus containing the lacZ marker gene (Ad5CMV-lacZ). ␤-gal-expressing areas were evaluated after injecting 2.4 ϫ 10 8 plaque-forming units of this vector into the tumors that had developed in the s.c. tissue of BALB/c nude mice. At 2 days after virus administration, ␤-gal staining performed on whole tumors revealed patches of lacZ-expressing cells around the injection points in the tumors (Fig 6B) .
Next, we examined the effects in vivo of GE alone and the combination with Ad5CMV-p53 that had been shown effective in vitro. To this end, tumors that developed in the s.c. tissue of BALB/c nude mice were treated with two different approaches (GE or GE plus Ad5CMV-p53). As shown in Figure 6A , marked reductions in tumor growth were observed in the two treated groups with respect to control animals. In addition, the presence of wt-p53 led to a significant improvement in the reduction of the growth rate of the GE-treated tumors, especially after the fourth administration. Interestingly, the mean volume of tumors treated with the combination approach decreased during the experiment.
DISCUSSION
The resistance of a significant percentage of pancreatic tumors to radiotherapy and chemotherapy makes this disease hard to treat. 2 The development of new therapeutic approaches is therefore particularly urgent. At present, protocols introducing the wt-p53 gene, which is the most frequently mutated gene in human cancers, 8, 9 are on the way; clinical trials, although preliminary, appear to be opening new avenues for cancer treatment. 6, 39 However, although the efficiency of p53 gene replacement has been unequivocally demonstrated in some kinds of tumors, 6, 27 thus providing a sound basis for clinical applications, 6 ,39 the results with regard to pancreatic cancer are controversial. [33] [34] [35] In addition, very few studies about the effects of combining p53 and chemotherapy have been undertaken in pancreatic tumors, and no reports on the correlation between growth inhibition, cell cycle, and apoptosis are available.
In the present study we have addressed some of these points. We have assayed different combination approaches based on wt-p53 gene reintroduction and genotoxic action. The drugs chosen (GE and CDDP) act on different targets, both leading to DNA damage that can be recognized by the p53 protein. Assays were performed on four pancreatic cell lines, three of them mutant p53 (NP-9, NP-18, and NP-31) and one harboring the wt-p53 gene (NP-29). Drug sensitivity does not appear to depend upon endogenous p53 status (see Table 1 ). GE is more powerful, showing IC 50 values in the nanomolar range. This result is maintained in all of the conditions assayed, in both the untransduced and the p53-transduced cells (see Table 2 ). This finding is consistent with the widespread use of this drug in current clinical therapy, especially in pancreatic tumors. 40 The ability of the recombinant adenovirus type 5 (Ad5) to infect pancreatic tumor cells is very high, as was evaluated previously using a reporter gene construct, Ad5CMV-lacZ. 35 This high transduction efficiency makes possible successful Ad-mediated p53 transfer at low viral doses. The wt-p53 protein was significantly increased in all infected cells (at least 10-fold over the endogenous level) and was maintained long enough to achieve marked effects on cell proliferation. 35 Moreover, p53 levels cannot be affected by the endogenous mechanisms that control the expression of the p53 gene. For this reason, the consequences of the reintroduction can differ significantly from the effects caused by endogenous p53 protein. p53 overexpression severely compromised the treatment with GE (see Fig 1A) . One of the causes of this chemoresistance can be found in the decrease in the S-phase population that follows the G 1 arrest induced by p53 overexpression (see Fig 1B) . The induced chemoresistance was as high as 14-fold for GE when deduced from the I max /IC 50 values (see Fig 1A) . Interestingly, changes in the value of I max /IC 50 , which reflects the overall efficiency of the drug, did not significantly differ from changes in the IC 50 . This is an indication that most of the chemoresistance comes from the decrease in the number of cells that are vulnerable to the effects of the S-phase-specific drugs, rather than from an alteration in the mechanisms of cell death. Indeed, the differences found between GE and CDDP behavior may be explained by the different degrees of S-phase specificity of these drugs. CDDP can exert its action on different phases of the cell cycle and, in consequence, the arrests provoked by p53 did not affect the sensitivity to this drug so significantly.
This interpretation was also corroborated by the effect of the introduction of p16
INK4a
, which specifically inhibits the function of cyclin-dependent kinase 4/6-cyclin D complexes, inducing G 1 arrest. 41 In this case, a significant degree of chemoresistance to GE was also achieved (see Fig 2) .
These results could explain the inability of the reintroduced wt-p53 to provide benefit in the treatment of pancreatic tumors, as reported by Kimura et al. 33 In these approaches, cells were exposed to drugs after gene transduction.
The second type of combination assayed in this study was much more effective. Results show that p53 recognizes DNA damage if it is reintroduced into cells that have already been treated with the drugs. In this case, both the IC 50 and I max /IC 50 indicated an increase in chemosensitivity. Again, the effect on GE sensitivity was much higher than the effect on CDDP sensitivity. In this case, a change in IC 50 values cannot be understood as an improvement of the interaction between the drug and the cells attributable to p53, as this protein is not present during drug treatment. Instead, lower IC 50 values would be an indication that cells are indeed damaged at low drug doses, but this effect is not translated into cell death. Only after p53 is reintroduced can damaged cells be committed to apoptosis. An even higher increase in chemosensitivity can be deduced from the I max /IC 50 value, thus indicating that together with the decrease in the IC 50 there is a significant increase in the I max that can be achieved by the drug. This result is also evident in Figures 1A and 3A , where the curve that corresponds to p53-transduced cells is below the control curve at all drug concentrations. It should be noted that the results shown in all of the dose-response curves are normalized to untreated p53-transduced cells as a reference value; therefore, the effects of p53 overexpression itself on cell growth are removed. The observed increase in chemosensitivity may thus be interpreted as a synergistic effect of the combination of p53 and the drugs. The lack of positive effects produced by transfection of the tumor suppressor p16 confirmed that this synergism is due to the role of p53 protein as an inductor of apoptosis in response to DNA damage.
Cell cycle analysis confirms that when p53 is reintroduced after drug exposure, G 1 arrest is not produced, thus indicating that the effects caused by the newly expressed wt-p53 are clearly dependent upon the cell environment. Instead, a population of the sub-G 1 region, indicative of apoptosis, appears in the transduced cells. Apoptosis was confirmed by annexin labeling (Table 3) . It should be noted that the percentage of early apoptotic cells could not be higher than the 40 -50% observed in NP-18 cells, considering that the method measures a transient population and cultures were growing asynchronously.
p53 strongly induces the expression of bax. 42 Thus, p53 appears to be an important regulator of apoptosis through the bax/bcl-2 balance, and any type of p53 inactivation could abrogate cell death through bax/bcl-2 imbalance, as recently confirmed in vivo. 43 Our results indicate that the bax/bcl2 balance is efficiently modulated by p53 expression when this gene is transduced after drug treatment, probably contributing significantly to the levels of apoptosis observed in mutant p53 cells.
The availability of a cell line bearing wt-p53 (NP-29) may introduce some concern in the analysis of the data reported here. NP-29 cells show no differences in sensitivity to the drugs assayed, as could be expected from the presence of endogenous wt-p53 (Table 1) . Moreover, this cell line appears to be insensitive to any effect of p53 reintroduction ( Table 2, Fig 4) . Because p53 is overexpressed in NP-29 cells at levels that are comparable with the other cell lines, the lack of response of NP-29 can be attributed to a dysfunction in the p53-dependent apoptotic pathways. Due to the key role of p53 in the control of cell proliferation and death, it is reasonable to hypothesize that the presence of functional p53 in a tumor cell could be an indication of alteration in other elements of p53-involving pathways. Although analysis of further examples is necessary, the behavior of NP-29 could be taken as a guide to the treatment of other tumor cells in which the p53-dependent pathway is altered, not necessarily due to the absence of p53 itself.
The data presented above indicate that exogenous p53 can efficiently recognize the DNA damage caused by even low doses of cytotoxic drugs, committing the affected cells to apoptosis. This effect can be revealed only if p53 is introduced after the drug treatment, because the arrest produced by p53 precludes the drug action, thus inducing chemoresistance. The synergistic effect, a consequence of the joint action of p53 and the drugs, facilitates the reduction of the drug dose required for effective treatments and, subsequently, eliminates some of the undesirable side effects.
Our findings provide a possible explanation for the previous discrepancies regarding the induction of chemoresistance or chemosensitization by p53, suggesting a mechanism whereby tumor cells can acquire resistance to anti-cancer agents. Indeed, it has been reported that CDDP administration simultaneously or subsequent to p53 gene replacement was less effective than sequential treatment in which CDDP was introduced first, but no explanation for these differences was proposed. 44, 45 Moreover, our results point out that combination therapies based on the use of GE and subsequent p53 delivery can be much more powerful than other treatments previously assayed with other drugs, such as CDDP. 6, 45 To assess the impact of this combination treatment in vivo, a preliminary experiment was performed. The first results are promising, because both GE alone and its combination with p53 significantly reduced tumor growth. The main limitation of in vivo gene therapy lies in the difficulty of delivering the therapeutic gene to the whole tumor. The area of the tumor transduced, as shown in the ␤-gal tumor staining, was small, in contrast to the high efficiencies obtained in vitro. Interestingly, despite this limitation, the viral-mediated reintroduction of p53 gene enhances the therapeutic effects of GE. After the end of the treatment, only the tumors treated with the combination maintained their size, whereas tumors treated with GE alone regained their growth rate. These differences are indicative of the ability of exogenous p53 to recognize DNA injury caused by drug treatment, leading to a situation in which new outbreaks of the tumors are less probable. An improvement in delivery strategies may be expected to lead to much better tumor remissions.
Taken together, our results suggest that it is possible to develop new rational therapeutic strategies based on combinations with p53. The introduction of wt-p53 gene via Ad5CMV-p53, under an appropriate schedule of administration, is a very promising approach to improve the efficiency of chemotherapeutic drugs.
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